Phathom Pharmaceuticals
PHAT
83 hedge funds and large institutions have $350M invested in Phathom Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 31 increasing their positions, 24 reducing their positions, and 13 closing their positions.
128,600% more call options, than puts
Call options by funds: $1.29M | Put options by funds: $1K
29% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 24
0% more funds holding
Funds holding: 83 → 83 (0)
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 13
9.92% less ownership
Funds ownership: 90.94% → 81.03% (-9.9%)
38% less capital invested
Capital invested by funds: $562M → $350M (-$212M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
A
Abingworth
London,
United Kingdom
|
+$3.75M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$3.12M |
| 3 |
Janus Henderson Group
London,
|
+$2.59M |
| 4 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$1.55M |
| 5 |
PMAM
Penn Mutual Asset Management
Conshohocken,
Pennsylvania
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$115M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$61.3M |
| 3 |
AG
Artal Group
Luxembourg
|
-$3.93M |
| 4 |
Ensign Peak Advisors
Salt Lake City,
Utah
|
-$3.41M |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$3.26M |
PHAT Hedge Fund Activity: Q1 2022 in Review
83 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Phathom Pharmaceuticals (PHAT) for Q1 2022, worth a combined $350M — down 38% from $562M a quarter earlier.
Fund positioning in PHAT was balanced in Q1 2022: 13 funds opened new positions, 13 closed out, 31 added to existing stakes and 24 trimmed.
The largest buyer was Abingworth, adding an estimated $3.75M. The largest seller was Frazier Management, exiting entirely with an estimated $115M sold.
- 83 institutional investors held Phathom Pharmaceuticals (PHAT) as of Q1 2022, unchanged from Q4 2021.
- Funds reported $350M of Phathom Pharmaceuticals stock for Q1 2022, down 38% quarter-over-quarter.
- 13 funds opened new Phathom Pharmaceuticals positions in Q1 2022 and 13 closed out, a net change of 0 holders.
- The largest Phathom Pharmaceuticals buyer in Q1 2022 was Abingworth, an estimated $3.75M added.
- The largest Phathom Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $115M sold.
Based on aggregated 13F filings for Q1 2022.